SCHEMBL24933272

SCHEMBL24933272

NC(=O)c1cc(-c2ccc(OCc3cnc4ccccn34)cc2)c(C(F)(F)F)[nH]c1=O

nearest known ligand 0.38

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ PLK1 P53350 1/20 0.38
▸ GGPS1 O95749 1/20 0.37
▸ FDPS P14324 1/20 0.37
▸ PDK1 Q15118 1/20 0.36
▸ PDK2 Q15119 1/20 0.36
▸ PDK3 Q15120 1/20 0.36
▸ PDK4 Q16654 1/20 0.36
▸ MAPT P10636 2/20 0.35
▸ NEK2 P51955 4/20 0.35
▸ DGAT2 Q96PD7 2/20 0.34
▸ GRM2 Q14416 1/20 0.34
▸ HSD17B1 P14061 2/20 0.34
▸ HSD17B2 P37059 2/20 0.34
▸ PRMT5 O14744 1/20 0.33
▸ WDR77 Q9BQA1 1/20 0.33
▸ TGFBR1 P36897 1/20 0.33
▸ NAMPT P43490 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24933006 0.82 KDM4E (0.51) —
SCHEMBL24933349 0.80 GSTP1 (0.50) HSD17B1HSD17B2
SCHEMBL24933222 0.80 PRKAB2 (0.44) HSD17B1HSD17B2
SCHEMBL30240779 0.79 PARP10 (0.51) —
SCHEMBL24933620 0.79 PARP10 (0.51) —
SCHEMBL24933376 0.79 HSD17B1 (0.38) HSD17B1HSD17B2
SCHEMBL24933463 0.78 HSD17B1 (0.41) HSD17B1HSD17B2PRMT5
SCHEMBL24933385 0.78 PARP1 (0.39) MAPTHSD17B1HSD17B2
SCHEMBL24932979 0.78 FFAR1 (0.42) GRM2HSD17B1HSD17B2
SCHEMBL30240777 0.78 PDE10A (0.39) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4373809-A1 SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS Novartis AG (CH) 2024-05-29 — — EP claimed
CN-117980292-A Substituted pyridone compounds for the treatment of orthomyxoviral infections 诺华股份有限公司 2024-05-03 — — CN claimed
WO-2023002443-A1 SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS NOVARTIS AG (CH) 2023-01-26 — — WO claimed
EP-4373809-A1 SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS Novartis AG (CH) 2024-05-29 — — EP disclosed
CN-117980292-A Substituted pyridone compounds for the treatment of orthomyxoviral infections 诺华股份有限公司 2024-05-03 — — CN disclosed
WO-2023002443-A1 SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS NOVARTIS AG (CH) 2023-01-26 — — WO disclosed
WO-2023002443-A1 SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS NOVARTIS AG (CH) 2023-01-26 — — WO disclosed
Send feedback